SCHEMBL7923262

SCHEMBL7923262

COC(=O)CC(NC(=O)c1ccncc1)C(C)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.45
KDM4E B2RXH2 2/20 0.45
MPO P05164 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2A6 P11509 1/20 0.45
CYP2C19 P33261 1/20 0.45
ALDH1A1 P00352 2/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
PTGS2 P35354 1/20 0.43
TSHR P16473 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GAA P10253 2/20 0.41
KCNA5 P22460 2/20 0.41
LMNA P02545 2/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7948541 0.88 CYP26A1 (0.47) KDM4EMPOCYP1A2CYP3A4ADORA3
SCHEMBL6048079 0.85 KMT2A (0.47) ALDH1A1GAALMNATDP1MEN1
SCHEMBL820939 0.84 SMN1; SMN2 (0.49) TP53CYP1A2CYP3A4CYP2C19ALDH1A1
SCHEMBL4028022 0.83 KMT2A (0.53) KDM4ECYP1A2CYP3A4ALDH1A1LMNA
SCHEMBL5219235 0.82 KMT2A (0.50) CYP1A2CYP3A4CYP2C19ALDH1A1TSHR
SCHEMBL6506417 0.82 CTSL (0.50) ALDH1A1GAALMNASMN1; SMN2HPGD
SCHEMBL10657225 0.82 HTT (0.53) KDM4EALDH1A1L3MBTL1GAALMNA
SCHEMBL5092483 0.77 MAOA (0.55) TP53KDM4EMPOCYP1A2CYP3A4
SCHEMBL4678063 0.77 LMNA (0.49) TP53CYP1A2CYP3A4CYP2C19ALDH1A1
SCHEMBL29788361 0.76 CYP26A1 (0.49) TP53KDM4EMPOCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6294580-B1 FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE GLAXO WELLCOME INC. 2001-09-25 US disclosed
EP-0888317-B1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LTD (GB) 2001-09-12 EP disclosed
EP-0888317-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1999-01-07 EP disclosed
WO-1997031907-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1997-09-04 WO disclosed